Tampa、FLにおける大うつ病性障害の臨床試験
Tampaとその周辺地域（約30マイル以内）の拠点で、大うつ病性障害に関する17件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
被験者募集中第3相
- IPTB Clinical Research, Tampa
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
被験者募集中第3相
- Psych Me Medical Research Inc, Tampa
- Interventional Psychiatry of Tampa Bay, Tampa
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
被験者募集中第2相
- K2 Medical Research - Tampa, Tampa
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
被験者募集中第3相
- Interventional Psychiatry of Tampa Bay, Tampa
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
被験者募集中第3相
- K2 Medical Research Tampa, Tampa
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
被験者募集中第4相
- Neurocrine Clinical Site, Tampa
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
被験者募集中第2相
- IPTB Clinical Research, Tampa
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
被験者募集中第2相
- Draig Clinical Site, Tampa
- Draig Clinical Site, Tampa
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
被験者募集中
- USF Health, Tampa
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
被験者募集中第3相
- Neurocrine Clinical Site, Tampa
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
被験者募集中第3相
- K2 Medical Research (Tampa), Tampa
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
被験者募集中第3相
- K2 Medical Research - Tampa, Tampa
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
被験者募集中第3相
- Neurocrine Clinical Site, Tampa
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
被験者募集中第3相
- Neurocrine Clinical Site, Tampa
- Neurocrine Clinical Site, Tampa
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
被験者募集中第2相
- University of South Florida, Psychiatry and Behavioral Neurosciences, Tampa
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
被験者募集中第2相
- Autobahn Site #148, Tampa
他の都市における大うつ病性障害の試験
- New York City, NY37件の研究
- Boston, MA31件の研究
- Atlanta, GA25件の研究
- Philadelphia, PA23件の研究
- Orlando, FL19件の研究
- Miami, FL18件の研究
- Chicago, IL17件の研究
- Houston, TX16件の研究
- San Diego, CA16件の研究
- Little Rock, AR14件の研究
- Orange, CA13件の研究
- Austin, TX13件の研究
Tampaにおける他の研究
- 非小細胞肺癌51件の研究
- 乳がん43件の研究
- がん（全種類）39件の研究
- 大腸癌33件の研究
- 転移性癌29件の研究
- 肺がん29件の研究
- 急性骨髄性白血病29件の研究
- 膵臓がん26件の研究
- 卵巣がん21件の研究
- 骨髄異形成症候群19件の研究
- 悪性黒色腫19件の研究
- 心不全18件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。